Why approval of KarXT, the first new drug for schizophrenia in decades, is a big deal
After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...
FDA Approves KarXT To Treat Schizophrenia; PureTech Health Gets $29 Mln Milestone Payment
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...
Managed Healthcare Executive16h
FDA Approves the Oral Medication KarXT for Schizophrenia
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
This FDA-approved drug promises a new way to treat schizophrenia
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...
Everyday Health8h
FDA Approves the First New Type of Schizophrenia Drug in Decades
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...
Deccan Herald16m
FDA approves the first new schizophrenia drug in decades
The Food and Drug Administration on Thursday approved the first novel antipsychotic treatment in decades, a drug developed to ...
Medscape14h
FDA OKs First-in-Class Antipsychotic for Schizophrenia
The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
PureTech Health celebrates KarXT approval by FDA for schizophrenia
PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone ...
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...
Science Media Centre18h
expert reaction to news that the FDA has approved the drug Cobenfy (KarXT) for schizophrenia
Scientists comment on the FDA approving Cobenfy (KarXT) for schizophrenia. Dr Sameer Jauhar, Senior Clinical Lecturer in Affective Disorders and Psychosis, Consultant Psychiatrist, King’s College, ...